Consumer health company Kenvue Inc. (NYSE:KVUE) on Thursday reported first-quarter 2025 sales of $3.74 billion, beating the consensus of $3.68 billion.
Some of Kenvue's most iconic brands include Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol.
Gross profit margin was 58.0% vs. 57.6% a year ago. Adjusted gross profit margin contracted 20 basis points vs. the prior year period to 60%.
Also Read: What Is The Tariff Risk For Procter & Gamble? Analyst Calculates, Trims Outlook
Operating income margin was 14.9% vs. 14.1%. Adjusted operating income margin was 19.8% vs. 22.0% in the prior year period.
The self-care segment recorded $1.67 billion in net sales, almost flat year over year. The skin health and beauty segment recorded a 7% drop in first-quarter net sales to $977 million. Essential Health segment sales decreased around 4% to $1.09 billion.
“In Q1, our teams executed our plans while continuing to navigate an evolving macro and consumer environment,” said Thibaut Mongon, CEO. “We are committed and focused on activating our brands while staying agile and flexible to accelerate sustainable, profitable growth.”
Guidance: Kenvue updated its fiscal 2025 outlook to reflect current foreign exchange rates and the estimated impact of higher costs due to tariffs. The company expects:
The company is working to reduce tariffs’ financial impact through several mitigation actions.
On Thursday, Kenvue appointed Amit Banati as the company’s CFO, effective May 12, 2025. Mr. Banati will succeed Paul Ruh.
In April, Kenvue announced a five-year collaboration with Microsoft to establish a strong foundation for transforming digital operations through advanced Artificial Intelligence (AI) technologies.
These technologies include machine-enabled collaboration, predictive analytics, smart agents, digital twins, and generative AI. By advancing predictive and AI-assisted capabilities, Kenvue aims to deliver enhanced consumer experiences, increased productivity, and sustained growth.
Over the next five years, Kenvue will scale its use of Microsoft Azure to capitalize on its wide range of services, including data analytics and AI.
Price Action: KVUE stock is up 6.30% at $24.57 at the last check on Thursday.
Read Next:
Photo by Colleen Michaels via Shutterstock
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。